AstraZeneca lifts 2024 outlook after Q3 beat, doubles down on US investments
By Maggie Fick and Yadarisa Shabong (Reuters) -Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong demand for its cancer and rare diseases medicines, after third-quarter results beat estimates. The London-listed company doubled down on plans for U.S. expansion, announcing $2 billion in new …
AstraZeneca lifts 2024 outlook after Q3 beat, doubles down on US investments Read More »









